Skip to Content

I-MAB ADR IMAB Stock Quote

| Rating as of


Last close prices updated as of Jan 27, 2023, 10:32 AM EST | USD | BATS BZX Real-Time Price
  • Last Close 6.41
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style
  • Day Range 6.34  –  6.84
  • Year Range 3.19  –  29.60
  • Market Cap 567.1579 Mil
  • Volume / Avg 109,588.0 /  515,766.7
  • Price / Sales 28.61
  • Price / Book 0.90
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis IMAB

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


I-Mab Faces Uncertainty in Its Global Pipeline

Jay Lee Senior Equity Analyst

Business Strategy and Outlook

| Jay Lee |

I-Mab Biopharma is a clinical-stage Chinese biotech firm with strong innovative products in its pipeline. Its first commercial drug will be felzartamab (CD38, Greater China), which could be launched in China at the end of 2023 or early 2024 for third-line multiple myeloma, or MM. Other core assets are lemzoparlimab (“lemzo”, CD47, Greater China), uliledlimab ("uli," CD73, global rights), and eftansomatropin (long-acting growth hormone, Greater China). Although we do not award I-Mab a moat due to the early stage of its portfolio, we are impressed with its differentiation and rational design and believe it has a positive moat trend.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics IMAB

Company Profile IMAB

Business Description

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.

555 West Haiyang Road, 55th - 56th Floor, New Bund Center, Pudong District
Shanghai, 200124, CHN
Industry Biotechnology
Employees 378

Related Articles IMAB

FAQs for I-MAB ADR Stock

No. IMAB does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

IMAB’s market cap is 567.16 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

IMAB’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare IMAB’s historical performance against its industry peers and the overall market.